Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Seminars in Oncology

• Publication date

  1999-06-01

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Apoferritin Nanocage Delivers Combination of Microtubule and Nucleus Targeting Anticancer Drugs.

  2016cites this paper
• Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity

  2008cites this paper
• Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy

  2007cites this paper
• Transoesophageal Echocardiography for Perioperative Haemodynamic Monitoring of Breast Carcinoma Patients with Neoadjuvant Chemotherapy

  2006cites this paper
• A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer

  2006cites this paper
• Taxane Therapy for Early Stage Breast Cancer

  2006cites this paper
• Pathologic Features of Breast Cancer Associated With Complete Response to Neoadjuvant Chemotherapy: Importance of Tumor Necrosis

  2005cites this paper
• Which dosing scheme is suitable for the taxanes? anin vitro model

  2002cites this paper
• Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

  2001cites this paper
• Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?

  2000cites this paper
• Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

  2000cites this paper
• Neue Zytostatika — Trends der Medikamentenentwicklung an der Jahrtausendwende

  2000cites this paper
• Issues in the treatment of metastatic breast cancer.

  2000cites this paper